Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

November 4, 2026

Consolidated Financial Results for the First Six Months of the Fiscal Year Ending March 31, 2027 (Under Japanese GAAP)

Listed Company: Zeria Pharmaceutical Co., Ltd. (Stock Exchange: Tokyo Stock Exchange)
Code Number: 4559 (URL: https://www.zeria.co.jp/english/)
Representative: Mitsuhiro Ibe, Representative Director, President & COO
Person in charge of reference: Koichi Tamura, Director, Public Relations Division TEL (03) 3661-1039
Scheduled date to submit the Semi-annual Securities Report: November 6, 2026
Scheduled date to commence dividend payments: December 1, 2026
Preparation of supplementary documents to the financial results: Yes
Holding of financial results presentation: Yes (for analysts, institutional investors and the press)

(Amounts under a million yen are truncated.)

1. Consolidated Financial Highlights (April 1, 2026 through September 30, 2026)

(1) Consolidated Financial Results (cumulative)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
Six months ended	Million yen	%	Million yen	%	Million yen	%	Million yen	%
September 30, 2026	45,461	13.8	5,646	55.1	5,191	95.4	3,959	127.8
September 30, 2025	39,960	(5.8)	3,641	(43.6)	2,656	(66.6)	1,737	(71.3)

Note: Comprehensive income: For the six months ended September 30, 2026: 3,813 million yen [24.1%]
For the six months ended September 30, 2025: 3,073 million yen [(68.3)%]

	Basic earnings per share	Diluted earnings per share
Six months ended	Yen	Yen
September 30, 2026	89.82	–
September 30, 2025	39.42	–

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio
As of	Million yen	Million yen	%
September 30, 2026	178,816	111,314	62.1
March 31, 2026	179,697	108,604	60.3

Reference: Equity: As of September 30, 2026: 111,083 million yen As of March 31, 2026: 108,396 million yen

2. Dividends

	Annual dividends				
	First quarter	Second quarter	Third quarter	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
Year ended March 31, 2026	–	24.00	–	25.00	49.00
Year ending March 31, 2027	–	25.00			
Year ending March 31, 2027 (Forecast)			–	26.00	51.00

Note: Revision of the forecast of dividends most recently announced: Yes
Regarding the revision to the dividend forecast, please refer to the “Notice Regarding Revision to Year-End Dividend Forecast (Increase)” announced today, November 4, 2026.

3. Consolidated Financial Forecast for Fiscal Year Ending March 31, 2027 (April 1, 2026 through March 31, 2027)

(Percentage figures indicate changes from the same period of the previous year.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	95,000	6.6	13,000	5.1	13,000	17.7	10,000	18.3	226.86

Note: Revision of the financial forecast most recently announced: None

* Notes

(1) Significant changes in the scope of consolidation during the period: None

Inclusion: – (Company name: –) Exclusion: – (Company name: –)

(2) Application of special accounting for preparing the semi-annual consolidated financial statements: Yes

Note: For details, please refer to "2. Semi-annual Consolidated Financial Statements and Significant Notes Thereto, (4) Notes to semi-annual consolidated financial statements (Notes on special accounting methods for preparation of semi-annual consolidated financial statements)" on page 9 of the Attached Material.

(3) Changes in accounting policies, changes in accounting estimates, and restatement of prior period financial statements after error corrections

1) Changes in accounting policies due to revisions to accounting standards and other regulations: None
2) Changes in accounting policies due to other reasons: None
3) Changes in accounting estimates: Yes
4) Restatement of prior period financial statements after error corrections: None

Note: For details, please refer to "2. Semi-annual Consolidated Financial Statements and Significant Notes Thereto, (4) Notes to semi-annual consolidated financial statements (Notes on changes in accounting estimates)" on page 9 of the Attached Material.

(4) Number of shares issued (common shares)

1) Number of shares issued as of the end of the term (including treasury shares):
As of September 30, 2026: 50,119,190 shares As of March 31, 2026: 50,119,190 shares
2) Number of shares of treasury shares as of the end of the term:
As of September 30, 2026: 6,039,802 shares As of March 31, 2026: 6,039,792 shares
3) Average number of shares during the period (cumulative from the beginning of the fiscal year):
For the six months ended September 30, 2026: 44,079,397 shares
For the six months ended September 30, 2025: 44,079,485 shares

* Semi-annual results reports are exempt from review conducted by certified public accountants or an audit corporation.

* Cautionary Statement with Respect to Appropriate Use of Financial Forecast and Other Special Matters

The description about the future including the projection in this document is based on information available to the Company at present and certain presumptions which the Company considers reasonable. Consequently, any descriptions herein do not constitute assurances regarding actual results by the Company. The actual results for future terms may differ from the information in this document due to various factors. For the assumptions made in financial forecasts and cautions concerning the use thereof, please refer to "1. Summary of Business Results (3) Explanation of consolidated financial forecasts and other forward-looking statements" on page 3 of the Attached Material.

○Table of contents of attachments

1. Summary of Business Results 2
   (1) Summary of business results for the semi-annual period under review 2
   (2) Overview of financial position for the semi-annual period under review 2
   (3) Explanation of consolidated financial forecasts and other forward-looking statements 3
2. Semi-annual Consolidated Financial Statements and Significant Notes Thereto 4
   (1) Semi-annual consolidated balance sheet 4
   (2) Semi-annual consolidated statement of income and semi-annual consolidated statement of comprehensive income 6
   Semi-annual consolidated statement of income 6
   Semi-annual consolidated statement of comprehensive income 7
   (3) Semi-annual consolidated statement of cash flows 8
   (4) Notes to semi-annual consolidated financial statements 9
   (Notes on changes in accounting estimates) 9
   (Notes on special accounting methods for preparation of semi-annual consolidated financial statements) 9
   (Notes on segment information, etc.) 10
   (Notes on significant changes in the amount of shareholders' equity) 11
   (Notes on premise of a going concern) 11
   (Notes on significant subsequent events) 11
3. Supplemental Information 12
   (1) Sales of major products and merchandise Consolidated 12
   (2) Status of pipeline of new drugs 13

1. Summary of Business Results

(1) Summary of business results for the semi-annual period under review

Net sales for the first six months of the fiscal year ending March 31, 2027 were 45,461 million yen (up 13.8% from the same period of the previous fiscal year). Operating profit was 5,646 million yen (up 55.1% from the same period of the previous fiscal year), ordinary profit was 5,191 million yen (up 95.4% from the same period of the previous fiscal year), and profit attributable to owners of parent was 3,959 million yen (up 127.8% from the same period of the previous fiscal year).

Below are the results by business segment.

(i) *Ethical Pharmaceuticals Business*

In overseas markets, the mainstay products Asacol and DIFICLIR performed favorably and drove business performance. In the domestic market as well, the business continued to perform solidly, driven partly by favorable trends for Veltassa, a therapeutic agent for hyperkalemia launched in March of last year.

As a result, net sales in the business amounted to 31,538 million yen (up 20.3% from the same period of the previous fiscal year).

(ii) *Consumer Healthcare Business*

Amid a slowdown in the growth of the overall OTC pharmaceutical market, and partly affected by unseasonable weather and the impact of competing products, mainstay products such as the Hepalyse range struggled. However, certain products such as the Royal Jelly range performed favorably, and the Chondroitin bulk business expanded overseas.

In addition, under the skincare brand IONA f, a new series IONA f RJ Derma, comprising all four products (a booster serum, medicated lotion, medicated emulsion, and medicated cream), was launched during the semi-annual period under review.

As a result, net sales in the business amounted to 13,848 million yen (up 1.3% from the same period of the previous fiscal year).

(iii) *Other*

Net sales in this segment amounted to 74 million yen (down 3.6% from the same period of the previous fiscal year), mainly due to insurance agency business and real estate lease revenue.

(2) Overview of financial position for the semi-annual period under review

(i) Assets, liabilities, and net assets

Total assets at the end of the semi-annual period of the fiscal year ending March 31, 2027 were 178,816 million yen, a decrease of 881 million yen from the end of the previous fiscal year. Current assets increased 3,208 million yen to 85,855 million yen from the end of the previous fiscal year, and non-current assets decreased 4,090 million yen to 92,960 million yen from the end of the previous fiscal year. The main changes in current assets included an increase of 1,399 million yen in cash and deposits, a decrease of 831 million yen in accounts receivable - trade, and an increase of 2,079 million yen in inventories such as merchandise and finished goods. The main changes in non-current assets were a decrease of 2,762 million yen in intangible assets and a decrease of 1,448 million yen in investments and other assets.

Total liabilities at the end of the semi-annual period under review were 67,501 million yen, a decrease of 3,591 million yen from the end of the previous fiscal year. Current liabilities decreased 1,119 million yen to 54,589 million yen from the end of the previous fiscal year, and non-current liabilities decreased 2,472 million yen to 12,912 million yen from the end of the previous fiscal year. The main changes in current liabilities were an increase of 853 million yen in accounts payable - trade, a decrease of 940 million yen in

short-term borrowings, a decrease of 644 million yen in income taxes payable, and a decrease of 525 million yen in provision for bonuses. The main changes in non-current liabilities were a decrease of 1,147 million yen in long-term borrowings and a decrease of 1,327 million yen in other of non-current liabilities, including a decrease in deferred tax liabilities.

Net assets at the end of the semi-annual period under review were 111,314 million yen, an increase of 2,710 million yen from the end of the previous fiscal year. This was mainly due to profit attributable to owners of parent of 3,959 million yen, payment of 1,101 million yen as dividends declared at the end of the previous period, a decrease of 767 million yen in valuation difference on available-for-sale securities, an increase of 1,076 million yen in foreign currency translation adjustment, and a decrease of 478 million yen in remeasurements of defined benefit plans.

As a result, the equity ratio at the end of the semi-annual period under review increased by 1.8 percentage points from the end of the previous fiscal year to 62.1%.

(ii) Status of cash flows

Cash and cash equivalents (below, "cash") at the end of the semi-annual period under review increased 1,399 million yen from the end of the previous fiscal year to 29,034 million yen. This was mainly due to net cash provided by operating activities of 5,642 million yen, despite net cash used in investing activities of 1,389 million yen and net cash used in financing activities of 3,166 million yen.

The status of each cash flow and its factors for the semi-annual period under review are as follows.

[Net cash provided by (used in) operating activities]

Net cash provided by operating activities amounted to 5,642 million yen in the semi-annual period under review (up 2,252 million yen from the same period of the previous fiscal year). This was due to factors including profit before income taxes of 5,191 million yen, depreciation of 4,249 million yen, a decrease in trade receivables of 1,147 million yen, an increase in inventories of 1,939 million yen, and income taxes paid of 2,749 million yen.

[Net cash provided by (used in) investing activities]

Net cash used in investing activities totaled 1,389 million yen in the semi-annual period under review (up 130 million yen from the same period of the previous fiscal year). This was mainly due to purchase of property, plant and equipment of 959 million yen and purchase of intangible assets of 430 million yen.

[Net cash provided by (used in) financing activities]

Net cash used in financing activities totaled 3,166 million yen in the semi-annual period under review (up 184 million yen from the same period of the previous fiscal year). This was mainly due to repayments of long-term borrowings of 1,712 million yen, and dividends paid of 1,097 million yen.

(3) Explanation of consolidated financial forecasts and other forward-looking statements

With regard to the business results for the semi-annual period under review, although ordinary profit fell slightly short of the plan due to the occurrence of foreign exchange losses, net sales, operating profit, and profit attributable to owners of parent progressed generally in line with the plan.

As business results are expected to proceed generally in line with the plan from the third quarter onward, the consolidated financial forecasts announced on May 8, 2026 remain unchanged at present. In addition, due to the uncertain outlook for foreign exchange rates, foreign exchange gains and losses have not been factored in.

2. Semi-annual Consolidated Financial Statements and Significant Notes Thereto

(1) Semi-annual consolidated balance sheet

(Thousands of yen)

	As of March 31, 2026	As of September 30, 2026
Assets		
Current assets		
Cash and deposits	27,760,027	29,159,745
Electronically recorded monetary claims - operating	35,486	51,193
Accounts receivable - trade	31,413,406	30,582,104
Merchandise and finished goods	10,994,264	10,780,268
Work in process	3,551,515	4,731,769
Raw materials and supplies	6,351,030	7,464,531
Other	3,200,118	3,734,989
Allowance for doubtful accounts	(658,965)	(648,735)
Total current assets	82,646,882	85,855,867
Non-current assets		
Property, plant and equipment		
Buildings, net	6,925,036	6,805,382
Land	12,663,993	12,665,099
Other, net	8,010,353	8,249,085
Total property, plant and equipment	27,599,383	27,719,567
Intangible assets		
Goodwill	3,027,507	2,664,394
Sales right	27,088,898	24,634,507
Other	9,465,382	9,520,360
Total intangible assets	39,581,788	36,819,261
Investments and other assets		
Investment securities	10,112,376	8,851,203
Retirement benefit asset	19,294,530	19,111,539
Other	492,075	488,082
Allowance for doubtful accounts	(29,086)	(29,011)
Total investments and other assets	29,869,895	28,421,812
Total non-current assets	97,051,067	92,960,642
Total assets	179,697,949	178,816,510
Liabilities		
Current liabilities		
Accounts payable - trade	4,895,991	5,749,146
Short-term borrowings	33,834,190	32,893,640
Income taxes payable	4,827,849	4,183,608
Provision for bonuses	1,778,324	1,253,078
Other	10,371,773	10,509,539
Total current liabilities	55,708,129	54,589,013
Non-current liabilities		
Long-term borrowings	5,269,740	4,121,920
Retirement benefit liability	201,368	203,932
Asset retirement obligations	56,629	56,694
Other	9,857,290	8,530,067
Total non-current liabilities	15,385,029	12,912,614
Total liabilities	71,093,159	67,501,628

(Thousands of yen)

	As of March 31, 2026	As of September 30, 2026
Net assets		
Shareholders' equity		
Share capital	6,593,398	6,593,398
Capital surplus	5,620,541	5,620,541
Retained earnings	73,545,791	76,402,871
Treasury shares	(12,204,622)	(12,204,642)
Total shareholders' equity	73,555,108	76,412,169
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	3,069,779	2,301,896
Foreign currency translation adjustment	24,628,069	25,704,662
Remeasurements of defined benefit plans	7,143,784	6,664,925
Total accumulated other comprehensive income	34,841,632	34,671,483
Non-controlling interests	208,048	231,229
Total net assets	108,604,790	111,314,882
Total liabilities and net assets	179,697,949	178,816,510

(2) Semi-annual consolidated statement of income and semi-annual consolidated statement of comprehensive income

Semi-annual consolidated statement of income

(Thousands of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Net sales	39,960,908	45,461,283
Cost of sales	11,169,685	13,279,288
Gross profit	28,791,222	32,181,995
Selling, general and administrative expenses	25,150,109	26,535,180
Operating profit	3,641,113	5,646,814
Non-operating income		
Interest income	57,850	53,105
Dividend income	251,217	285,991
Other	131,176	62,256
Total non-operating income	440,243	401,353
Non-operating expenses		
Interest expenses	240,107	280,690
Foreign exchange losses	1,057,838	399,622
Other	127,129	176,183
Total non-operating expenses	1,425,075	856,496
Ordinary profit	2,656,282	5,191,672
Extraordinary losses		
Loss on sale of non-current assets	22	—
Loss on retirement of non-current assets	2,833	0
Total extraordinary losses	2,855	0
Profit before income taxes	2,653,426	5,191,672
Income taxes	1,007,002	1,216,400
Profit	1,646,424	3,975,272
Profit (loss) attributable to non-controlling interests	(91,257)	16,206
Profit attributable to owners of parent	1,737,682	3,959,065

Semi-annual consolidated statement of comprehensive income

(Thousands of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Profit	1,646,424	3,975,272
Other comprehensive income		
Valuation difference on available-for-sale securities	378,571	(767,883)
Foreign currency translation adjustment	1,342,145	1,084,632
Remeasurements of defined benefit plans, net of tax	(293,400)	(478,858)
Total other comprehensive income	1,427,316	(162,108)
Comprehensive income	3,073,740	3,813,163
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	3,189,443	3,788,916
Comprehensive income attributable to non-controlling interests	(115,702)	24,246

(3) Semi-annual consolidated statement of cash flows

(Thousands of yen)

	Six months ended September 30, 2025	Six months ended September 30, 2026
Cash flows from operating activities		
Profit before income taxes	2,653,426	5,191,672
Depreciation	3,165,021	4,249,750
Amortization of goodwill	354,469	369,119
Increase (decrease) in provision for bonuses	(453,338)	(539,538)
Increase (decrease) in retirement benefit liability	(4,533)	2,564
Interest and dividend income	(309,067)	(339,096)
Interest expenses	240,107	280,690
Foreign exchange losses (gains)	446,056	(159,582)
Decrease (increase) in trade receivables	2,326,671	1,147,862
Decrease (increase) in inventories	(2,908,200)	(1,939,582)
Increase (decrease) in trade payables	967,276	804,202
Decrease (increase) in other current assets	(485,080)	(565,890)
Increase (decrease) in other current liabilities	(804,175)	290,975
Decrease (increase) in retirement benefit asset	(280,799)	(509,990)
Other, net	(26,869)	45,894
Subtotal	4,880,964	8,329,052
Interest and dividends received	308,927	339,191
Interest paid	(245,992)	(276,745)
Income taxes paid	(1,553,780)	(2,749,321)
Net cash provided by (used in) operating activities	3,390,119	5,642,176
Cash flows from investing activities		
Payments into time deposits	(125,000)	(125,000)
Proceeds from withdrawal of time deposits	125,000	125,000
Purchase of property, plant and equipment	(1,272,304)	(959,668)
Purchase of intangible assets	(247,292)	(430,577)
Other, net	(62)	755
Net cash provided by (used in) investing activities	(1,519,658)	(1,389,490)
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	(419,000)	(114,600)
Repayments of long-term borrowings	(1,663,500)	(1,712,420)
Repayments of lease liabilities	(209,923)	(240,600)
Purchase of treasury shares	(90)	(20)
Dividends paid	(1,055,667)	(1,097,336)
Dividends paid to non-controlling interests	(2,717)	(1,039)
Net cash provided by (used in) financing activities	(3,350,899)	(3,166,016)
Effect of exchange rate change on cash and cash equivalents	540,456	313,047
Net increase (decrease) in cash and cash equivalents	(939,982)	1,399,718
Cash and cash equivalents at beginning of period	23,467,676	27,635,027
Cash and cash equivalents at end of period	22,527,694	29,034,745

(4) Notes to semi-annual consolidated financial statements

(Notes on changes in accounting estimates)

Regarding the sales right for the product DIFICLIR held by the Company's subsidiary Tillotts Pharma AG, the Company has been amortizing it by estimating the useful life based on the period over which economic benefits are expected to be generated. However, due to an increased possibility of generic drug entry in the future, the useful life has been shortened, and this change is being applied prospectively.

As a result, operating profit, ordinary profit, and profit before income taxes for the semi-annual period under review each decreased by 779,854 thousand yen.

(Notes on special accounting methods for preparation of semi-annual consolidated financial statements)

Calculation of tax expenses

Tax expenses were calculated by reasonably estimating the effective tax rate after applying tax effect accounting to the profit before income taxes for the fiscal year that includes the semi-annual period of the current fiscal year and multiplying profit before income taxes by such estimated effective tax rate.

(Notes on segment information, etc.)

[Segment information]

I First six months of the previous fiscal year (from April 1, 2025 to September 30, 2025)

1. Information on net sales and profit or loss by reportable segment

(Thousands of yen)

	Reportable segment			Other (Note 1)	Total	Adjustment (Note 2)	Amount recorded in semi-annual consolidated statement of income (Note 3)
	Ethical Pharmaceuticals Business	Consumer Healthcare Business	Total				
Net sales							
Sales to external customers	26,208,664	13,675,354	39,884,019	76,889	39,960,908	—	39,960,908
Intersegment sales and transfers	—	48	48	239,130	239,178	(239,178)	—
Total	26,208,664	13,675,402	39,884,067	316,019	40,200,087	(239,178)	39,960,908
Segment profit	3,422,072	3,170,897	6,592,969	88,531	6,681,501	(3,040,387)	3,641,113

(Notes) 1. "Other" is a business segment not included in the reportable segments and includes the insurance agency business and real estate business.

2. Adjustment of segment profit of (3,040,387) thousand yen is mainly corporate expenses, such as general and administrative expenses that are not allocated to reportable segments.

3. Segment profit is adjusted with operating profit in the semi-annual consolidated statement of income.

2. Information on impairment losses on non-current assets or goodwill by reportable segment

Not applicable.

II First six months of the current fiscal year (from April 1, 2026 to September 30, 2026)

1. Information on net sales and profit or loss by reportable segment

(Thousands of yen)

	Reportable segment			Other (Note 1)	Total	Adjustment (Note 2)	Amount recorded in semi-annual consolidated statement of income (Note 3)
	Ethical Pharmaceuticals Business	Consumer Healthcare Business	Total				
Net sales							
Sales to external customers	31,538,301	13,848,865	45,387,166	74,117	45,461,283	—	45,461,283
Intersegment sales and transfers	—	49	49	224,806	224,855	(224,855)	—
Total	31,538,301	13,848,914	45,387,215	298,923	45,686,139	(224,855)	45,461,283
Segment profit	5,883,986	2,968,420	8,852,407	99,535	8,951,942	(3,305,128)	5,646,814

(Notes) 1. "Other" is a business segment not included in the reportable segments and includes the insurance agency business and real estate business.

2. Adjustment of segment profit of (3,305,128) thousand yen is mainly corporate expenses, such as general and administrative expenses that are not allocated to reportable segments.

3. Segment profit is adjusted with operating profit in the semi-annual consolidated statement of income.

2. Information on impairment losses on non-current assets or goodwill by reportable segment

Not applicable.

(Notes on significant changes in the amount of shareholders' equity)

Not applicable.

(Notes on premise of a going concern)

Not applicable.

(Notes on significant subsequent events)

Business combination by acquisition

Tillotts Pharma AG, the Company's Swiss consolidated subsidiary, entered into an equity interest purchase agreement on October 23, 2026 (Swiss time) to acquire all equity interests of Haupt Pharma Wülfling GmbH from Aenova Holding GmbH.

For more details, please see the Notice Concerning Acquisition of Equity Interests of Haupt Pharma Wülfling GmbH (Making It a Sub-subsidiary) by a Consolidated Subsidiary announced on October 26, 2026.

3. Supplemental Information

(1) Sales of major products and merchandise Consolidated

(Thousands of yen)

	First six months of the previous fiscal year (from April 1, 2025 to September 30, 2025)	First six months of the current fiscal year (from April 1, 2026 to September 30, 2026)	Percentage change (%)
1. Ethical Pharmaceuticals Business	26,208,664	31,538,301	20.3
Asacol	9,843,956	12,544,095	27.4
DIFICLIR	9,852,150	11,797,307	19.7
Entocort	1,850,690	1,840,951	(0.5)
Acofide	1,568,239	1,600,407	2.1
Other	3,093,627	3,755,539	21.4
2. Consumer Healthcare Business	13,675,354	13,848,865	1.3
Hepalyse range	6,427,756	6,324,189	(1.6)
Chondroitin range	2,897,235	2,852,835	(1.5)
WithOne range	737,757	699,937	(5.1)
Other	3,612,604	3,971,903	9.9
3. Other Business	76,889	74,117	(3.6)
Total	39,960,908	45,461,283	13.8

(2) Status of pipeline of new drugs

I. Domestic

As of November 4, 2026

Stage	Development Code/Generic Name	Development	Indications	Classification	Origin
NDA filed	Z-338/Acotiamide	Zeria	Pediatric functional dyspepsia	Upper gastrointestinal motility modulator	Original
Phase II	ZG-802/Acotiamide	Zeria	Underactive bladder	Lower urinary tract function modulator	Original
Phase II (Specified Clinical Trial)	Z-100	Nonprofit Organization, North East Japan Study Group	Non-small cell lung cancer	Immunomodulator	Original

II. Overseas

Stage	Development Code/Generic Name	Development	Indications	Classification	Origin
NDA approved (Costa Rica)	Z-338/Acotiamide	Faes Farma	Functional dyspepsia	Upper gastrointestinal motility modulator	Original (Out-licensed)
NDA filed (Vietnam)	Z-338/Acotiamide	Pharmaceutical Joint Stock Company of February 3rd	Functional dyspepsia	Upper gastrointestinal motility modulator	Original
NDA filed (Colombia, Panama)	Z-338/Acotiamide	Faes Farma	Functional dyspepsia	Upper gastrointestinal motility modulator	Original (Out-licensed)
Phase III (Europe, United States, Canada)	Z-338/Acotiamide	Agastra-Lab s.r.l.	Functional dyspepsia	Upper gastrointestinal motility modulator	Original (Out-licensed)

Launched

Launch Date	Development Code/Generic Name	Development	Indications	Classification	Origin
August 2026 (Nicaragua)	Z-338/Acotiamide	Faes Farma	Functional dyspepsia	Upper gastrointestinal motility modulator	Original (Out-licensed)